Why Cyclopharm (ASX: CYC) is a whopping 21% higher today!

Nick Sundich Nick Sundich, July 4, 2022

Cyclopharm (ASX: CYC), a radiopharmaceutical company responsible for the lung ventilation imaging product Technegas, has risen over 15% today in light of a revenue update. The company has left investors disappointed over the delays in obtaining FDA approval for Technegas, hence its decline in recent months. However, today’s gain depicts investors are finally realising a fact about the company they have disregarded all along.

Pitt Street Research just published a research update on CYC last week!

 

cyclopharm chart

Cyclopharm (ASX:CYC) chart (Graph: TradingView)

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

Cyclopharm hasn’t got FDA approval for Technegas 

Technegas is a gas-like, radioactive compound delivered throughout the pathways of a lung, allowing a gamma camera to create a functional ventilation image of the lung and diagnose problems, such as pulmonary embolisms. 

Cyclopharm has been trying to get FDA approval since 2007 and its long-term efforts haven’t born fruit – now it won’t get approval until at least 2023. 

 

But it has 60 other markets 

But investors who have exited the company have forgotten that Technegas is already sold in 60 other markets. This morning, the company announced unaudited revenues for the half year to 30 June 2022. It reported record revenues of $1.3m, up 36% compared to the prior corresponding period.  

The company also told shareholders it was on track to obtain FDA approval and then enter the US market in mid-2023. It has a cash balance of $26m, which it told shareholders should be sufficient until it obtains FDA approval.  

Shareholders can expect the company’s audited half yearly results by the end of August.

Check out our interview with Cyclopharm’s management here! 

Disclosure: Pitt Street Research/Stocks Down Under directors own CYC shares.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Recent Posts

Toubani Resources

Toubani Resources (ASX:TRE) gets ready for the big time in Mali

Toubani Resources (ASX:TRE) is another aspiring gold producer. What’s not to love about an aspiring gold producer right now? Its…

Capricorn Metals

Capricorn Metals (ASX:CMM): Its sequel gold mine will be even better than the original

Capricorn Metals (ASX:CMM) is one of several gold miners on the ASX that has slid under the radar of many…

Price to Book

Here’s why the Price to Book (P/B) multiple is so important to know if you own shares in the Big 4 Banks

If you own shares ASX Bank stocks (especially the big Four), you need to know about the P/B multiple (Price…